Systemic Scleroderma Clinical Trial
Official title:
Evaluation of the Efficacy of Sildenafil on Time to Healing in Patients With Scleroderma and Ischaemic Digital Ulcers: a Prospective, Longitudinal, Randomized, Comparative, Double-blind, 2-parallel-arm, Placebo-controlled Study
Digital ulcers (DUs) are an expression of the microangiopathy in patients with scleroderma (SSc). DUs lead to pain and impaired hand use. DUs remain a severe complication for many patients and effective therapy remains elusive. In the present study, the investigators propose to evaluate the efficacy of Sildenafil in DUs healing in a randomized double blind control study in SSc patients.
This is a multicenter, prospective, longitudinal, randomized, comparative, double-blind,
2-parallel-arm, placebo-controlled study aimed to evaluate the efficacy of sildenafil 20 mg
TID study on time to healing of DUs in SSc patients with ischaemic DUs.
Approximately 120 patients aged from 18 years and above will be allocated to receive either
placebo or sildenafil 20mg TID during 90 days. All potential subjects will present with
ischaemic digital ulcers complicating scleroderma. An eligible digital ulcer must be beyond
the proximal interphalangeal joint, on finger surface (included periungual ulcers), of
ischemic origin according to the physician, and not over subcutaneous calcifications or bone
relief.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03629002 -
BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA
|
||
Terminated |
NCT00377455 -
Placebo Controlled Trial of Bosentan in Scleroderma Patients
|
Phase 2 | |
Completed |
NCT00278525 -
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
|
Phase 2 | |
Completed |
NCT00318188 -
Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
|
N/A | |
Completed |
NCT03575156 -
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
|
N/A | |
Active, not recruiting |
NCT01413100 -
Scleroderma Treatment With Autologous Transplant (STAT) Study
|
Phase 2 | |
Completed |
NCT00622895 -
Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03816189 -
Role of Eosinophil in Fibrogenesis of Systemic Sclerosis
|
||
Completed |
NCT02213705 -
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT03508375 -
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
|
N/A | |
Active, not recruiting |
NCT01309997 -
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
|
Phase 2 | |
Completed |
NCT00697736 -
Cardiac Repercussion of Systemic Sclerodermias
|
N/A | |
Completed |
NCT02349009 -
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
|
Phase 1/Phase 2 | |
Completed |
NCT00318175 -
Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis
|
Phase 2 | |
Completed |
NCT03262922 -
Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment
|
||
Recruiting |
NCT03816345 -
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
|
Phase 1 | |
Recruiting |
NCT04380831 -
TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
|
Early Phase 1 | |
Terminated |
NCT00628797 -
Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT05672992 -
Longitudinal Spatial Frequency Domain Imaging Study
|
N/A | |
Recruiting |
NCT05726630 -
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
|
Phase 3 |